Fintel reports that on February 4, 2025, Piper Sandler downgraded their outlook for Amphastar Pharmaceuticals (NasdaqGS:AMPH) ...

Piper Sandler cut shares of Amphastar Pharmaceuticals (NASDAQ:AMPH – Free Report) from an overweight rating to a neutral rating in a research note issued to investors on Tuesday, Marketbeat reports.

On Tuesday, Piper Sandler adjusted its stance on Amphastar Pharmaceuticals (NASDAQ:AMPH), downgrading the company's stock rating from Overweight to Neutral and significantly reducing the price ...

On Tuesday, Piper Sandler adjusted its stance on Amphastar Pharmaceuticals (NASDAQ:AMPH), downgrading the company's stock rating from Overweight to Neutral and significantly reducing the price target ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Morgan Stanley upgraded Palantir (PLTR) to Equal Weight from Underweight with a price target of $95, up from $60, following ...

Check the time stamp on this data. Updated AI-Generated Signals for Amphastar Pharmaceuticals Inc. (AMPH) available here: AMPH. Type a few symbols and Take a Trial. The signals for these will appear ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...